#United States #Morristown #Whitehawk Therapeutics #ADC therapies #PTK7

Whitehawk Therapeutics Unveils Key Findings at World Conference on Lung Cancer 2026

Introduction

Whitehawk Therapeutics, a clinical-stage leader in oncology therapeutics, delivered compelling insights at the IASLC World Conference on Lung Cancer (WCLC) held in Seoul from September 12-15, 2026. The focus was on protein tyrosine kinase 7 (PTK7) as an important target for antibody-drug conjugates (ADCs) in the treatment of EGFR wild-type non-small cell lung cancer (NSCLC).

Findings on PTK7 Expression

The data presented highlighted that PTK7 expression is notably stable after standard-of-care therapies such as chemotherapy and immunotherapy. This stability is critical, as it indicates that PTK7 remains a viable target for therapeutic engagement even after patients have undergone multiple lines of treatment. This research, led by Dr. Margaret Dugan, the Chief Medical Officer at Whitehawk, underscores the importance of PTK7 in developing next-generation ADCs like HWK-007.

The study involved analyzing tumor samples from patients with EGFR wild-type lung adenocarcinoma, revealing that PTK7 expression exhibited less variation than several other ADC targets currently under late-stage development, such as MET and PD-L1. Importantly, the presence of PTK7 expression remained consistent across various tumor subgroups, irrespective of the presence of actionable genomic alterations.

Clinical Relevance of PTK7

One major emphasis of the findings is that PTK7 functions as a target-engagement biomarker rather than a prognostic marker for survival outcomes in patients with advanced EGFR wild-type lung adenocarcinoma. This was established through a real-world analysis that indicated no significant impact of PTK7 expression on overall or progression-free survival among patients who were treated with second- or later-line therapies. Rather, clinical outcomes were largely dictated by established prognostic factors, further demonstrating the unique role of PTK7 in treatment scenarios.

Dr. Aaron Lisberg from UCLA contributed to this discussion, noting that the persistent presence of therapeutic targets like PTK7 is especially important as patients progress through various lines of treatment in advanced lung cancer cases.

Implications for ADC Development

HPK-007, targeting PTK7, is currently undergoing clinical trials for various cancer indications, including platinum-resistant ovarian and endometrial cancers. The results presented at WCLC significantly bolster the scientific rationale for HWK-007’s continued development in targeting PTK7. These findings facilitate a better understanding of how ADC therapy could effectively engage identified targets in patients with difficult-to-treat NSCLC.

In conclusion, the research presented by Whitehawk Therapeutics at the WCLC 2026 not only highlights the clinical potential of PTK7 as a durable ADC target but also paves the way for innovative cancer treatment strategies tailored to the patient population historically underserved by conventional therapies. This evolving landscape promises to bring hope for improved patient outcomes in the realm of lung cancer treatment.

Future Directions

As Whitehawk Therapeutics continues to navigate the clinical landscape with its innovative ADCs, further studies exploring the molecular mechanisms underlying PTK7’s behavior in treatment settings will be essential. The collaboration with Tempus AI will likely yield more insights, potentially leading to breakthrough advancements in personalized cancer therapies.

Visit Whitehawk Therapeutics for more information about their pioneering work in oncology therapeutics.